Senesco to Present at Annual OneMedPlace Finance Forum

Jan 05, 2010, 08:00 ET from Senesco Technologies, Inc.

NEW BRUNSWICK, N.J. Jan. 5 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) announced today that the Company will be presenting at the Annual OneMedPlace Finance Forum, which is being held at the Sir Francis Drake Hotel in San Francisco, CA. Harlan W. Waksal, M.D., Senesco's Chairman of the Board, will deliver the Company's corporate presentation on Tuesday, January 12th, at 9:15 AM PT.

Held annually in San Francisco, the OneMedPlace Finance Forum was created to connect emerging healthcare and life science companies with investors and strategic partners. Over 100 company presentations will occur by some of the most promising -- and typically least recognized -- companies in the world.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, our ability to maintain our continued listing standards for the next 12 months, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.


    Company Contact:             Investor Relations Contact:
    ----------------             ---------------------------
    Senesco Technologies, Inc.   FD
    Joel Brooks                  Brian Ritchie
    Chief Financial Officer      (brian.ritchie@fd.com)
    (jbrooks@senesco.com)        (212) 850-5600
    (732) 296-8400

SOURCE Senesco Technologies, Inc.



RELATED LINKS

http://www.senesco.com